DocG DocG | AI-Powered Clinical Summaries
Sign In

Stay Current with Medical Literature

AI-powered clinical summaries delivered to your inbox 3 times per week. Evidence-based insights in 300 words, designed for busy physicians.

Sign Up

See What You Get

Subscribers receive email summaries and access to our interactive AI-powered article rankings.

Email Summary Example

SGLT2 inhibitors slow kidney disease progression
SGLT2 inhibitors lowered kidney failure and slowed kidney decline across a wide range of baseline kidney function and urine albumin levels.
*Meta-analysis of randomized, double-blind, placebo-controlled trials; Level 1a (OCEBM).

Citation

Neuen BL, Fletcher RA, Anker SD, et al; SMART-C. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. JAMA. 2026;335(3):233-244. Published online November 7, 2025. doi:10.1001/jama.2025.20834

Background

These diabetes medicines (SGLT2 inhibitors) are known to protect kidneys, but benefits in advanced kidney disease or with little to no urine albumin have been uncertain. This study tested whether baseline kidney filtering rate or urine albumin level changes the kidney benefit.

Patients

70,361 adults in 10 randomized trials (35% female; mean age 64.8 years) with type 2 diabetes, chronic kidney disease, or heart failure. Exclusions: trials with fewer than 500 participants per group, follow-up under 6 months, or kidney outcomes not systematically collected; excluded drugs without an approved kidney indication.

Intervention

Canagliflozin, dapagliflozin, or empagliflozin.

Control

Placebo.

Outcome

Primary: chronic kidney disease progression (kidney failure, ≥50% drop in kidney filtering rate, or death due to kidney failure). Secondary: kidney failure alone; serious sudden kidney injury; yearly rate of kidney filtering decline.

Follow-up Period

At least 6 months (varied by trial).

Results

Outcome Effect (SGLT2 inhibitor vs placebo) Absolute effect
Chronic kidney disease progression (primary) Hazard ratio 0.62 (95% CI, 0.57-0.68) 25.4 vs 40.3 events per 1000 patient-years; NNT ≈ 67 per year
Kidney failure alone Hazard ratio 0.66 (95% CI, 0.58-0.75) —
Serious sudden kidney injury Hazard ratio 0.74 (95% CI, 0.66-0.82) —
Yearly kidney filtering decline (slope) 51% slower decline (95% CI, 49%-54%) 1.26 mL/min/1.73 m2/year less decline
Effects on chronic kidney disease progression were consistent across baseline kidney filtering rate and urine albumin subgroups, including stage 4 chronic kidney disease and minimal albumin in the urine. Analyses used an intention-to-treat approach.

Limitations

Not a full systematic review; trials were limited to a consortium. Very limited data for starting treatment when kidney filtering rate was under 20. Few primary-outcome events in participants without diabetes and with normal urine albumin reduced certainty for that subgroup.

Funding

No industry funding for meta-analysis; included trials were industry funded.

Clinical Application

Use SGLT2 inhibitors for kidney protection across chronic kidney disease stages and urine albumin levels when eligible; do not withhold solely due to stage 4 disease.

Top Journal Rankings - March 2026

1317 abstracts scored across 7 criteria. Click any article to expand criterion scores.
1. 8.4
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
Overall: This large randomized trial with blinded outcome assessment found a clinically meaningful absolute reduction in clinically relevant bleeding with apixaban versus rivaroxaban for acute VTE over 3 months, using outcomes and treatments that are highly applicable and easy to implement in routine outpatient care.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.0
Acute VTE treatment with DOACs is a common outpatient/transition-of-care decision relevant to generalists, though diagnosis/risk stratification may involve specialty or ED pathways.
Validity, Bias Control & Precision 8.5
Large international randomized trial with blinded end-point assessment (PROBE design) and clear effect estimate with tight CI for the primary outcome; open-label treatment introduces some performance/ascertainment risk for nonmajor bleeding but is mitigated by blinded adjudication.
Patient-Oriented Outcomes 8.0
Primary endpoint is clinically relevant bleeding (major plus clinically relevant nonmajor), which is patient-important; all-cause mortality is reported but rare and imprecise.
Magnitude of Net Benefit 8.5
Clinically relevant bleeding was lower with apixaban (3.3% vs 7.1%; RR 0.46), an absolute reduction of 3.8% over 3 months with no clear signal of excess non-bleeding serious adverse events reported in the abstract.
Implementability & Practicality 9.0
Both regimens use widely available oral agents with standard dosing and no unusual monitoring described, making switching toward the lower-bleeding option straightforward in routine care.
Practice-Changing Potential 8.5
Head-to-head randomized evidence showing a meaningful bleeding reduction is likely to shift DOAC selection for acute VTE toward apixaban in typical practice, subject to individual patient factors and formulary/cost constraints (not detailed in the abstract).
2. 8.2
Infant Outcomes, Risk Factors, and Diagnostic Yield After a Brief Resolved Unexplained Event: A Systematic Review and Meta-Analysis.
Overall: A large, GRADE-assessed meta-analysis reports rare mortality, a small but important prevalence of serious diagnoses, identifies a few higher-risk features, and shows routine tests have very low yield—evidence likely to reduce unnecessary workups and inform guideline updates, though based mostly on observational studies.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.5
BRUE evaluation and decisions about risk stratification and diagnostic testing commonly involve outpatient pediatrics/primary care (often alongside ED care), and the findings directly inform what tests a generalist should or should not order.
Validity, Bias Control & Precision 8.0
Large systematic review/meta-analysis (24 studies; 6603 infants) with random-effects pooling, CIs, and GRADE certainty ratings, but evidence is largely observational and data extraction was done by 1 reviewer (verified by a second), which can increase error risk.
Patient-Oriented Outcomes 8.5
Primary outcomes include serious underlying diagnoses and 3-month mortality—highly patient-important endpoints—along with clinically meaningful prognostic factors and testing yield.
Magnitude of Net Benefit 7.5
It shows mortality is exceedingly rare and routine tests have extremely low diagnostic yield (e.g., metabolic panels 0% yield; ECG 0.2%; CXR 0.4%), supporting reduced low-value testing and associated false positives/burden, though it does not directly test an intervention strategy’s outcomes.
Implementability & Practicality 9.0
The main actionable implication is de-implementation of routine testing and use of a targeted, risk-informed approach, which is straightforward to apply and likely reduces costs and unnecessary follow-up.
Practice-Changing Potential 8.0
By quantifying risk factors and demonstrating very low yields of common investigations with reasonably high certainty, it provides strong support for revising protocols away from blanket testing in a common, anxiety-provoking presentation.
3. 8.2
Oral anticoagulant monotherapy in patients with chronic coronary disease: An updated meta-analysis.
Overall: This RCT-only meta-analysis suggests OAC monotherapy meaningfully lowers bleeding without increasing major ischemic outcomes, making it a practical, potentially practice-changing simplification for many chronic coronary disease patients needing long-term anticoagulation.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.5
Chronic coronary disease patients on long-term anticoagulation are commonly comanaged in outpatient settings, and decisions about continuing or stopping antiplatelet therapy often involve generalists, though cardiology context is frequent.
Validity, Bias Control & Precision 8.0
An updated meta-analysis limited to randomized trials (5 RCTs, n=4964) with clear effect estimates and confidence intervals supports credibility, but the abstract does not report heterogeneity, risk-of-bias assessment, or trial-level limitations.
Patient-Oriented Outcomes 9.0
Outcomes include death, myocardial infarction, stroke, systemic embolism, and major bleeding—directly patient-important endpoints rather than surrogates.
Magnitude of Net Benefit 7.5
Major bleeding is substantially reduced (RR 0.49) without apparent increases in ischemic events, suggesting meaningful net benefit, though absolute event rates and absolute risk differences are not provided.
Implementability & Practicality 9.0
The strategy is a simplification (OAC alone vs adding an antiplatelet), which is straightforward to implement clinically and likely reduces monitoring and bleeding-management burden.
Practice-Changing Potential 8.0
Findings support dropping routine antiplatelet therapy in a common high-risk population, which could change prescribing patterns, though the abstract alone does not address key subgroups or guideline alignment.
4. 8.2
Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
Overall: This multicenter randomized trial shows that NOAC monotherapy beyond 1 year after drug-eluting stent in atrial fibrillation meaningfully lowers net clinical events—driven by much less bleeding—while remaining noninferior/superior to adding clopidogrel, and it is easy to implement in outpatient care.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.0
Atrial fibrillation anticoagulation and long-term post-stent antithrombotic decisions are common outpatient issues, though many patients are co-managed with cardiology and the setting is post–drug-eluting stent.
Validity, Bias Control & Precision 8.0
Multicenter randomized trial with a clear comparator and prespecified noninferiority margin; open-label design introduces some potential bias, but event rates and confidence intervals suggest reasonably precise estimates in 960 patients.
Patient-Oriented Outcomes 8.0
Outcomes include death, MI, stroke/systemic embolism, stent thrombosis, and clinically relevant bleeding—highly patient-important, although combined in a composite endpoint.
Magnitude of Net Benefit 9.0
Monotherapy reduced the primary composite (9.6% vs 17.2%; absolute difference −7.6%) and substantially reduced major/clinically relevant nonmajor bleeding (5.2% vs 13.2%), indicating a large net benefit with less treatment burden.
Implementability & Practicality 9.0
Switching from NOAC plus clopidogrel to NOAC alone is straightforward, uses common medications, and typically reduces monitoring and pill burden compared with combination therapy.
Practice-Changing Potential 8.0
A sizeable reduction in clinically important events and bleeding in a randomized NEJM trial is likely to increase clinician confidence in NOAC monotherapy beyond 1 year post-stent, though generalizability beyond the South Korea population may be a consideration.
5. 8.2
Nudges to Clinicians and Patients for Influenza Vaccines During Visits: The BE IMMUNE Randomized Clinical Trial.
Overall: This large pragmatic primary-care randomized trial shows a modest but meaningful absolute increase in influenza vaccination uptake using scalable EHR- and text-based nudges, with precise effect estimates, though it reports a process outcome rather than direct clinical endpoints and provides little information on harms or burden.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.5
Conducted across 48 primary care clinics in patients ≥50 years due for influenza vaccine at scheduled primary care visits, directly aligning with routine primary-care preventive care decisions.
Validity, Bias Control & Precision 8.5
Pragmatic randomized clinical trial with a very large sample (80,039) and reported adjusted effects with tight 97.5% CIs; cluster randomization and adjustment support credibility, though blinding is not described and the primary outcome is behaviorally influenced.
Patient-Oriented Outcomes 6.0
Outcome is vaccine completion (process/behavior), not downstream clinical endpoints (influenza illness, hospitalization, mortality) or patient-reported outcomes.
Magnitude of Net Benefit 7.5
Absolute increase in vaccination of 5.1 percentage points (31.4% vs 26.4%) is clinically meaningful for population prevention; harms, burdens, and unintended consequences (e.g., alert fatigue, messaging burden) are not reported in the abstract.
Implementability & Practicality 8.5
Uses common, scalable tools in many systems (previsit texts, EHR pended orders, peer comparison feedback), feasible for large outpatient practices, though it requires EHR build and operational support.
Practice-Changing Potential 9.0
Large pragmatic primary-care trial shows a clear, statistically robust improvement in vaccination uptake, offering a ready-to-adopt strategy; also suggests bidirectional texting adds no benefit in a targeted subgroup.
6. 8.1
Mobile Chat Messaging for Smoking Relapse Prevention: A Randomized Clinical Trial.
Overall: This randomized trial with biochemical validation shows a clinically meaningful increase in 6-month abstinence using chat-based relapse prevention, with strong internal credibility and good feasibility, though implementation resources and unreported harms/costs limit certainty about real-world rollout.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.0
Smoking relapse prevention is a common, high-impact outpatient problem; although delivered via clinic-based cessation services, the intervention (messaging support) is broadly relevant to primary-care tobacco treatment follow-up.
Validity, Bias Control & Precision 8.5
Randomized clinical trial with intention-to-treat analysis, excellent 6-month retention (98%), and biochemical validation of the primary endpoint; estimates include CIs and appear reasonably precise for the sample size (n=590).
Patient-Oriented Outcomes 8.5
Outcomes are directly patient-important (validated abstinence and relapse), not just surrogate biomarkers, with clearly defined endpoints at 6 months.
Magnitude of Net Benefit 8.5
Validated abstinence improved by an absolute 10.4% (45.9% vs 35.5%) and relapse decreased (33.0% vs 44.9%), suggesting a clinically meaningful benefit; however, adverse effects, patient burden, and costs were not reported in the abstract.
Implementability & Practicality 7.5
Delivery through a messaging app is practical and potentially scalable, but the live counselor component implies staffing/workflow needs beyond fully automated texting, which may limit easy adoption in all settings.
Practice-Changing Potential 7.5
A well-conducted RCT showing meaningful improvements in abstinence could change how relapse prevention is offered after quitting, though generalizability outside the studied cessation-service context and resource needs may temper immediate uptake.
7. 8.0
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Overall: A large, rigorous IPD meta-analysis of double-blind statin trials provides precise evidence that most labeled adverse effects are not causally increased, with only small absolute excesses for a few outcomes, making it highly usable for primary-care counseling and potentially practice-influencing.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.0
Statin prescribing and adverse-effect counseling are routine primary-care tasks, and the results directly inform shared decision-making about common patient concerns (eg, cognitive symptoms, sleep disturbance).
Validity, Bias Control & Precision 9.5
Individual participant data meta-analysis of large double-blind randomized trials (≥1000 participants, ≥2 years) with very large total sample (n=123,940) and reported RRs with 95% CIs plus false-discovery-rate control supports strong credibility and precision.
Patient-Oriented Outcomes 6.5
Many assessed outcomes are symptoms/conditions patients care about (eg, depression, cognitive impairment, oedema), but several significant findings are laboratory abnormalities (liver tests, urinary composition), which are less directly patient-important in the abstract.
Magnitude of Net Benefit 7.0
Most labeled adverse effects were not supported in blinded trials, suggesting reduced net harm concerns; the statistically significant excesses reported appear small in absolute terms (eg, combined liver test abnormality annual excess 0.13%; oedema RR 1.07).
Implementability & Practicality 9.0
Findings are readily implementable as updated counseling and risk communication without new equipment, workflows, or monitoring beyond usual statin care; they may also inform regulatory labeling.
Practice-Changing Potential 8.0
If incorporated into official labeling and clinician counseling, the evidence could meaningfully change how clinicians address common statin intolerance narratives and potentially improve acceptance/adherence, although it does not introduce a new treatment strategy.
8. 7.8
Age-Adjusted D-Dimer Cutoff Levels to Rule Out Deep Vein Thrombosis.
Overall: A large prospective multicenter study suggests age-adjusted D-dimer can safely increase DVT rule-out without additional imaging in low/unlikely patients, with patient-important follow-up outcomes and high practical feasibility, though nonrandomized design and limited harm reporting temper certainty.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.0
Addresses a common diagnostic question (suspected DVT) using tools generalists often initiate, though the population was emergency-department outpatients rather than primary-care clinics.
Validity, Bias Control & Precision 8.0
Large, multicenter prospective management-outcome design with standardized strategy and 3-month follow-up; not randomized, but estimates are reasonably precise (e.g., 0% failures with CI reported).
Patient-Oriented Outcomes 8.0
Primary outcome was adjudicated symptomatic venous thromboembolic events during follow-up, a directly patient-important safety endpoint.
Magnitude of Net Benefit 7.0
Meaningfully increases the proportion of patients ruled out without imaging (notably in those ≥75 years) with no observed failures, though the confidence interval allows for a small miss rate and harms/burdens are not fully detailed.
Implementability & Practicality 9.0
Uses readily available components (Wells score, high-sensitivity D-dimer, ultrasound) and a simple age-based cutoff that is easy to apply in routine workflows.
Practice-Changing Potential 8.0
Provides prospective validation supporting adoption of age-adjusted D-dimer for suspected DVT, likely to reduce unnecessary imaging/testing in older adults.
9. 7.8
Intensive Blood Pressure Control and Cardiovascular Outcomes Across Cardiovascular-Kidney-Metabolic Syndrome Stages: A Post Hoc Analysis of the China Rural Hypertension Control Project.
Overall: A large post hoc analysis of a cluster RCT suggests intensive BP control (<130/80) reduces cardiovascular events across CKM stages with increased hypotension but otherwise similar harms, offering fairly strong, implementable evidence with moderate practice-changing impact.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.0
Addresses outpatient hypertension management in a large community-based population, using a team-based model (trained nonphysician practitioners) that maps to real-world primary-care workflows, though conducted in rural China which may limit direct generalizability elsewhere.
Validity, Bias Control & Precision 8.5
Based on a large cluster randomized clinical trial dataset with ~3 years follow-up and precise estimates (n=33,736; tight CIs), but this is a post hoc secondary analysis, which increases risk of multiplicity and less certain prespecification.
Patient-Oriented Outcomes 8.5
Uses clearly patient-important endpoints (MACE composite including stroke/MI/HF/CV death and all-cause mortality) plus tangible harms (hypotension, syncope, injurious falls, kidney events).
Magnitude of Net Benefit 7.5
Shows substantial relative reductions in cardiovascular events across CKM stages (HRs ~0.61–0.71) with increased hypotension risk (RR ~1.79–2.34) and otherwise similar adverse events; however, absolute event rates are not provided, making clinical magnitude and tradeoffs harder to judge.
Implementability & Practicality 8.0
Intervention targets a common BP goal (<130/80) and is delivered via trained nonphysician practitioners, suggesting scalability; still, it is a “comprehensive” intensive strategy that likely requires structured follow-up and medication titration capacity.
Practice-Changing Potential 6.5
Supports intensive BP control across CKM stages with consistent effects, which could influence management of high-risk multimorbidity, but findings are post hoc and intensive BP targets are already widely discussed/used, limiting how decisively this alone would shift practice.
10. 7.8
Effect of the Telemedicine Enhanced Asthma Management-Uniting Providers (TEAM-UP) Program on Asthma Outcomes: A Randomized Clinical Trial.
Overall: A reasonably powered randomized trial shows patient-important improvements in pediatric asthma outcomes with a school-based DOT plus specialist telemedicine model, but real-world adoption may be constrained by logistical and staffing requirements and limited reporting on harms.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.5
Addresses pediatric moderate-severe/poorly controlled asthma and outcomes relevant to outpatient longitudinal care, but the intervention is school-based and specialist-telemedicine–anchored rather than a typical primary-care clinic workflow.
Validity, Bias Control & Precision 8.5
Randomized clinical trial with a moderate sample size (n=326) and reported effect estimates with 95% CIs for key outcomes; some implementation variability is evident (not all received DOT; pandemic interruptions), and blinding is not described.
Patient-Oriented Outcomes 9.0
Primary and secondary outcomes are patient-important (symptom-free days, missed school, ED visits/hospitalizations) rather than purely physiologic surrogates.
Magnitude of Net Benefit 7.5
Shows clinically meaningful improvements: +1.32 symptom-free days per 2 weeks and reduced odds of missed school and ED/hospital use; harms are not reported, and the intervention likely adds burden (DOT plus specialist tele-visits).
Implementability & Practicality 6.5
Requires coordination with schools, daily directly observed therapy, and access to asthma specialists via telemedicine—feasible in some systems but with notable logistical and staffing barriers.
Practice-Changing Potential 8.0
Demonstrates improved symptoms and reduced acute care use in an underserved, largely Medicaid population, supporting a scalable care model where school-health infrastructure exists, though broad adoption may be limited by resources.
Score Guide: 9-10 Exceptional 7-8 Strong 5-6 Moderate 3-4 Weak 1-2 Poor
Showing top 10 of 1317

How It Works

1

Sign Up with Google

Create your account in seconds using your Google account. No passwords to remember.

2

Receive Email Summaries

Get AI-curated clinical summaries delivered to your inbox three times per week (Monday, Wednesday, Friday).

3

Find the Best New Articles

Our interactive article rankings allow you to find the best articles, tailored to you.

Ready to Stay Current?

Sign Up